ERBB2 and breast carcinoma: In vitro experiments demonstrated the specific high-affinity binding of PE38KDEL-loaded PLGA Nps to breast cancer cells overexpressing HER2; the antitumor activity of PE38KDEL-loaded PLGA Nps was higher and nonspecific toxicity was lower than that of free PE38KDEL immunotoxin.